Drug Claim Symptoms Spread Among Supplement Marketers Targeting Ebola Fears
This article was originally published in The Pink Sheet Daily
Executive Summary
The latest FDA/FTC joint warning letters advise Life Silver, Bodyhealth.com LLC and Ebola-C Inc. that their online claims render their products unapproved new drugs. FDA directs the firms to respond to an “EbolaTaskForce-CFSAN” email address rather than to an ORA address typical of most warning letters.
You may also be interested in...
Ebola Crisis Causes Drug Claim Symptoms In Products Marketed As Supplements
FTC joins FDA in one of the three warning letters to firms claiming their products can either prevent or treat Ebola. One firm’s website offers a video titled, “Urgent Message to Ebola-Stricken Nations' Heads of State,” and another claims “primary uses for oregano include athlete’s foot, candida, canker sores, Ebola virus.”
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.